Skip to main content
Plaque PsoriasisDrugPhase 3

What this study is

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

What's being tested

  • Deucravacitinib

    Intervention · DRUG

  • Ustekinumab

    Intervention · DRUG

Both interventions

Specified dose on specified days

Study details

Official title
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants With Moderate-to-Severe Plaque Psoriasis
Sponsor
Bristol-Myers Squibb
Conditions
Plaque Psoriasis
Enrolling
3,040 people
Starts
2025-09-22
Est. completion
2031-01-16
Design
Open-label, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗